Vitamin D levels in COVID-19 patients [COVID-19}
Research type
Research Study
Full title
An observational study investigating the role of serum vitamin D levels in morbidity and mortality of patients diagnosed with COVID-19 in secondary care in the north-west of England
IRAS ID
285337
Contact name
Edward Jude
Contact email
Sponsor organisation
Tameside and Glossop Integrated Care NHS Foundation Trust
Clinicaltrials.gov Identifier
NCT04386044, clinicaltrials.gov
Duration of Study in the UK
0 years, 2 months, 31 days
Research summary
Research Summary:
The 2019 novel coronavirus disease (COVID-2019) pandemic is an enormous health issue of worldwide scale. Prevention and/or treatment with a widely-available and already-licensed product such as vitamin D (cholecalciferol) could have a large impact on healthcare worldwide. Given ethnic variation in vitamin D production, this could help to address the discrepancies in how people of different ethnicities are affected by COVID-19. Furthermore, there are currently no published studies analysing individual-level evidence on the effect of vitamin D status on COVID-19 outcomes.The study will recruit patients hospitalised with COVID-19. Vitamin D levels will be measured in these patients and compared with outcome measures of COVID-19 severity. Data will be collected from a mixture of patient medical records, electronic patient records, laboratory data and from patients themselves. Data will be analysed with a combination of linear and logistic regression, as appropriate, and with adjustment for covariates.The primary objectives are to determine whether vitamin D levels affect outcomes in COVID-19 infection and whether vitamin D deficiency is associated with increased risk.Summary of Results:
In conclusion, high-dose cholecalciferol booster therapy, regardless of baseline serum 25(OH)D levels, appears to be associated with a reduced risk of mortality in acute in-patients admitted with COVID-19. This suggests that further work should be carried out to determine what an adequate serum level of 25(OH)D might be from large-scale population studies, and paves the way for future clinical trials of cholecalciferol therapy, at multiple doses in order to assess maximum efficacy. This inexpensive and widely available treatment could have positive implications for the management of COVID-19 worldwide, particularly in developing nations.REC name
Wales REC 3
REC reference
20/WA/0176
Date of REC Opinion
23 Jun 2020
REC opinion
Further Information Favourable Opinion